**Background**

*Acinetobacter baumannii* of the *Acinetobacter spp* is a ubiquitous aerobic gram-negative bacillus which preferentially colonizes aquatic environments. Recently, the bacterium has become an important opportunistic pathogen primarily associated with hospital-acquired infections (HAIs). Patients usually affected are those critically ill having been admitted to the intensive care unit (ICU) and often receiving mechanical ventilation. In these instances *A.baumannii* related pneumonia can have high mortality rates of 50% or above. *A.baumannii* hospital infections can be difficult to treat with current antibiotics especially multidrug resistant forms MDR, XDR and PDR. In addition, such infections dramatically increase hospital length of stay (LOS) and economic cost.

There are many drivers to justify the search for new management techniques to *A.baumannii* infections. The development of a prophylactic vaccine is one plausible option especially in light of industry major player efforts directed to *Staphylococcus aureus* and *Clostridium difficile* (C.diff) vaccines.

This MarketVIEW product is composed of a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of *Acinetobacter baumannii* vaccines across major Western markets to 2030. Three scenarios (LO, BASE and HI) are included based upon successive targeting of patient groups who would benefit from vaccination. A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach. An ideal Target Product Profile (TPP) is defined along with commercial model assumptions with economic pricing justification.
Methodology

*VacZine Analytics* has closely monitored all significant source material pertaining to hospital (nosocomial) vaccines and novel approaches. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by *VacZine Analytics* in the field of bacterial/nosocomial vaccines has also been utilised.

PRODUCT CONTENTS:
Published October 2016 (CAT No: VAMV070)

****This product is composed of one forecast model¹ and a summary presentation²:

Contents
Author's note
Executive summary
Key commercial model outputs
A. baumannii vaccine - potential revenues per scenario to 2030
A. baumannii vaccine - potential volumes per scenario to 2030
A. baumannii vaccine - potential revenues per country to 2030 (base)
A. baumannii vaccine - potential volumes per country to 2030 (base)
A. baumannii vaccine - addressable patients (000s) 2020, US
A. baumannii vaccine - price versus efficacy curve
Acinetobacter baumannii - disease background
Acinetobacter baumannii - the pathogen
Colonization rates of Acinetobacter baumannii
A. baumannii - infection types
Risk factors for A. baumannii infections and/or colonizations
A. baumannii - transmission
Multi drug resistant (MDR) A.baumannii
Multi drug resistant (MDR) A.baumannii – exacerbating factors
MDR A. baumannii - global outbreaks
A. baumannii - main patient populations and settings
A. baumannii - hospital (ICU setting)
A. baumannii - hospital (ICU setting), by infection site
A. baumannii - hospital (ICU setting), risk factors
A. baumannii - hospital (non-ICU setting)
Distribution of A.baumannii isolates by hospital ward, Mexico 2000-2011¹
Surgical patients and A.baumannii infection
A. baumannii - trauma/disaster/conflict setting
A. baumannii - community setting
Acinetobacter baumannii - epidemiology
A.baumannii - key numbers
A. baumannii - global epidemiology (overview)
% Acinetobacter species per ICU infection type 1975-2003

¹ Model contents available upon request
² Presentation titles may apply to more than one slide
Continued......

A. baumannii - global prevalence (EPIC II study)
Multi drug resistant (MDR) A.baumannii – prevalence
Carbapenem resistant Acinetobacter - MYSTIC, 2004¹
(MDR) A.baumannii - mortality rate, mean length of stay
Incidence density of carbapenem-resistant AB, Italy 2008-13¹
A.baumannii infection - trends and dynamics
Reasons for increased A.baumannii infection
Economic burden
Comparative economic cost with other hospital pathogens
United Nations - General Assembly, September 2016
Acinetobacter baumannii - current treatment and management
Case study: Valneva AG - IC43-201 Phase II Study
How could a A.baumannii vaccine be used in the ICU?
Vaccination to prevent A.baumannii CAP (HI SCENARIO)
A. baumannii vaccine forecast model: methodology
A. baumannii vaccine forecast model: general assumptions
Forecast vaccine population flow (base case)
Detailed commercial model assumptions (base case)
Detailed commercial model assumptions (high and low case)
Summary of commercial model scenarios
Summary of vaccine coverage rates applied
High-level pharmacoeconomic analysis: ICU-VAP
US economic burden of VAP and potential cost savings
Risks and challenges
Model caveats and limitations
Bibliography
Disclaimer
About VacZine Analytics

Slide number = 88
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD $9995.00/ GBP £7870.00# (Region license)*

# Indicative company rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total
Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY

28. Andres MA et al. DIFFERENCES IN ACINETOBACTER BAUMANNII INFECTION ACCORDING TO ADMISSION PLACE: INTENSIVE CARE UNIT OR MEDICAL/SURGICAL WARD. ESCMID Poster.
29. Otero MO et al. Acinetobacter baumannii Infections in a Tertiary Care Hospital in Mexico over the Past 13 Years. Chemotherapy 2013;59:57-65
32. Otero MO et al. Acinetobacter baumannii Infections in a Tertiary Care Hospital in Mexico over the Past 13 Years. Chemotherapy 2013;59:57-65
34. Chen SJ et al. Predictors of mortality in surgical patients with Acinetobacter baumannii bacteremia. Journal of Microbiology, Immunology and Infection (2011) 44, 209e214
56. Antimicrobial Resistance and Infection Control 2015 4:43
77. VacZine Analytics. MarketVIEW: Staphylococcus aureus vaccines (CAT No: VAMV002), published April 2012
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.

3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.

5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.

6. If not purchased on line invoices are payable within thirty days of the invoice date.

7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.

8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.

9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

www.vacZine-analytics.com
Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44 (0) 1279 654514 e-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009